GlobeNewswire

ADC Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

Del

Potential new immune-oncology therapy uses antibody drug conjugate (ADC) that targets regulatory T cells (Tregs)

Highly potent anti-tumor activity of CD25-targeted ADC demonstrated in preclinical solid tumor models both as monotherapy and in combination with a PD-1 inhibitor

Company plans to initiate Phase Ib clinical trial to evaluate safety, tolerability and preliminary anti-tumor activity of ADCT-301 (camidanlumab tesirine) in patients with advanced solid tumors

LAUSANNE, Switzerland, Nov. 08, 2018 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced it will present two posters highlighting preclinical data and the Phase Ib clinical trial design for ADCT-301 (camidanlumab tesirine) in advanced solid tumors at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, which is being held November 7-11 in Washington, DC.

Jay Feingold, MD, PhD, Chief Medical Officer and Senior Vice President of Clinical Development at ADC Therapeutics, said, “ADCT-301 is already being evaluated in relapsed and refractory Hodgkin lymphoma, and at the 2018 American Society of Hematology (ASH) Annual Meeting we will be updating our abstract data from June, at which time we had an overall response rate of 80.8 percent with a complete response rate of 50 percent in median 6th line patients. Based on the immune-oncology potential ADCT-301 demonstrated in preclinical studies, we are excited to be starting a clinical trial for ADCT-301 in solid tumors to see if we can make an impact and improve patient outcomes in multiple solid tumor cancers.”

Patrick van Berkel, PhD, Senior Vice President of Research and Development at ADC Therapeutics, said, “ADCT-301 targets CD25, which is expressed on Tregs that infiltrate the local tumor environment.  In preclinical models, a single dose of the CD25-targeted ADC induced strong and durable anti-tumor activity against established CD25 negative solid tumors with infiltrating Tregs. Moreover, re-challenged mice did not develop new tumors indicating the CD25-targeted ADC was able to induce tumor-specific protective immunity.”

ADC Therapeutics’ posters will be located in Poster Hall E in the Walter E. Washington Convention Center. The Poster Hall will be open Friday, November 9 from 8 a.m. to 8 p.m. and Saturday, November 10 from 8 a.m. to 8:30 p.m. EST. Details of the posters are below.

Abstract Poster Number: P11
Title: A CD25 targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate shows potent anti-tumor activity in pre-clinical models of solid tumors either alone or in combination with a PD-1 inhibitor
Presentation Date and Time: Friday, November 9, 12:45-2:15 p.m. and 6:30-8 p.m. EST
Presenter: Francesca Zammarchi, PhD, ADC Therapeutics

Abstract Poster Number: P316
Title: Phase 1b dose-escalation and dose-expansion study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-301 (camidanlumab tesirine) in patients with advanced solid tumors
Presentation Date and Time: Saturday, November 10, 12:20-1:50 p.m. and 7-8:30 p.m. EST
Presenter: Francesca Zammarchi, PhD, ADC Therapeutics

For more information about the SITC 2018 Annual Meeting, please visit https://www.sitcancer.org/2018/home.

About ADCT-301

ADCT-301 (camidanlumab tesirine) is an antibody drug conjugate (ADC) composed of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to the pyrrolobenzodiazepine (PBD) dimer payload tesirine. Once bound to a CD25-expresing cell, ADCT-301 is internalized into the cell where enzymes release the PBD-based warhead. The intra-tumor release of its PBD warhead may cause bystander killing of neighboring tumor cells. In addition, the PBD warhead will trigger immunogenic cell death, which in turn will strengthen the immune response against tumor cells. ADCT-301 is being evaluated in a Phase Ib clinical trial in solid tumors (NCT03621982), as well as ongoing Phase Ia/Ib clinical trials in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma (NCT02432235).

About ADC Therapeutics

ADC Therapeutics SA is an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs) targeting major hematological malignancies and solid tumors. The Company’s ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads via a chemical linker. The Company has multiple PBD-based ADCs in ongoing clinical trials in the USA and Europe, and a deep pipeline of other preclinical ADCs in development. ADCT has world-class partners, including AstraZeneca and its global biologics research and development arm, MedImmune. The Company is based in Lausanne (Biopôle), Switzerland and has operations in London, San Francisco and New Jersey. For more information, visit www.adctherapeutics.com.

Investors Contact                                           
Dr. Chris Martin                                                               
Chief Executive Officer                                 
Chris.martin@adctherapeutics.com Tel.: +41 (0) 21 653 0200                  

EU Media Contact          
Alexandre Müller           
Dynamics Group              
amu@dynamicsgroup.ch 
Tel: +41 (0) 43 268 3231          

USA Media Contact
Tony Plohoros
6 Degrees
tplohoros@6degreespr.com Tel.: +1 908-591-2839        

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

DATE 2019: eSilicon to present two papers on advanced floor planning techniques with the Polytechnic University of Catalonia21.3.2019 01:35:00 CETPressemelding

BARCELONA, Spain, March 20, 2019 (GLOBE NEWSWIRE) -- What: eSilicon, a leading provider of FinFET-class ASICs, market-specific IP platforms and advanced 2.5D packaging solutions, with the Polytechnic University of Catalonia, Barcelona, Spain are presenting two papers on advanced floor planning techniques at DATE 2019, Florence, Italy. Who: Alex Vidal-Obiols, Jordi Cortadella, Jordi Petit, Department of Computer Science, Universitat Politècnica de Catalunya. Marc Galceran-Oms, Ferran Martorell, eSilicon EMEA, Barcelona, Spain. RTL-Aware Dataflow-Driven Macro Placement This paper proposes a novel multi-level approach for macro placement of complex designs dominated by macro blocks, typically memories. Using the hierarchy tree, the netlist is divided into blocks containing macros and standard cells and their dataflow affinity is inferred considering the latency and flow width of their interaction. This information, known by the RTL designer, is often lost during physical synthesis. The la

More than 200 million Android users in Europe will soon be asked to choose their new favorite browser20.3.2019 18:41:00 CETPressemelding

OSLO, Norway, March 20, 2019 (GLOBE NEWSWIRE) -- Soon, more than 200 million Android users in Europe will be able to choose their favorite browser. In a blog post, Google has outlined that it will “...do more to ensure that Android phone owners know about the wide choice of browsers and search engines available to download to their phones. This will involve asking users of existing and new Android devices in Europe which browser and search apps they would like to use.” The announcement follows a July 2018 decision of the European Commission which prompted Google to change its licensing model for Google apps built for Android phones. “Competition is essential for making better products. When people get to make a choice between competing apps, they will be able to choose the best app for their use, and not just the app that is presented as the system default, “ said Krystian Kolondra, EVP Opera browsers, “We believe this step on Android can help Europeans more easily discover and choose

UPDATE - Eurotunnel entrusts the mid-life renovation of its Passenger Shuttles to Bombardier Transportation20.3.2019 12:53:00 CETPressemelding

BERLIN, March 20, 2019 (GLOBE NEWSWIRE) -- As part of the 2018-2026 mid-life programme, Eurotunnel signed a contract with Bombardier Transportation to renovate nine “PAX” Shuttles. Composed in total of 254 wagons, each 800-meter long shuttle is made up for passengers’ vehicles with passengers remaining in their vehicles during for the 35-minute Channel crossing. In the 25-year period since the opening of the Channel Tunnel, these Shuttles have each travelled an average of 300 round trips per month and have enabled over 236 million passengers to travel very comfortably between France and Great-Britain. The contract is valued at €150 million ($171 million) over a period of seven years. Deliveries of the newly refurbished Shuttles will start in mid-2022 and continue until mid-2026. Teams from Bombardier France and Belgium1 originally designed and built these unique vehicles in the 90’s and launched Bombardier’s activities in France. This year, the company celebrates 30 years since its est

Consumers Love Messaging for Customer Service But Hate its Experience Silo20.3.2019 11:30:00 CETPressemelding

YouGov survey of US and UK consumers reveals that lack of consistent omnichannel experience is the biggest hurdle to faster adoption of messaging for customer service SUNNYVALE, Calif. and NEWBURY, United Kingdom, March 20, 2019 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN), the leading provider of digital-first, omnichannel customer engagement hubs, today announced the findings based on a consumer survey of the use of messaging for customer service. The survey revealed that consumers love the convenience of messaging but struggle mightily with its experience silo. Conducted by YouGov on behalf of eGain, the survey was based on responses from 1777 consumers who messaged a business for customer service in the last 12 months. When asked about their struggles1 when messaging businesses for customer service: 43% hated repeating information across agents or when escalating to other channels; 28% struggled with the speed of response; and 23% were stumped by the relevance of response. Another inte

IMImobile announces availability of its enterprise communications platform IMIconnect on Salesforce AppExchange20.3.2019 09:00:00 CETPressemelding

IMIconnect’s AppExchange app enables Salesforce users to automate two-way customer interactions across 10+ communication channels LONDON, March 20, 2019 (GLOBE NEWSWIRE) -- IMImobile today announced the availability of its enterprise cloud communications platform IMIconnect on Salesforce AppExchange. This can enable businesses utilising the Salesforce Platform to rapidly launch and orchestrate two-way, trigger-based customer communications, across 10+ communication channels including SMS, WhatsApp, Apple Business Chat, In App and Push, amongst others. The IMIconnect for Salesforce App will augment the existing customer interaction capabilities of Salesforce Service Cloud, Sales Cloud, Commerce Cloud and Field Service Lightning to enable proactive customer engagement and reduce the cost of serving customers across touchpoints. Enterprises will be able to automate communications, such as order and delivery notifications for retailers, engineer appointment bookings for utility providers a

Eurotunnel entrusts the mid-life renovation of its Passenger Shuttles to Bombardier Transportation20.3.2019 08:30:00 CETPressemelding

BERLIN, March 20, 2019 (GLOBE NEWSWIRE) -- As part of the 2018-2026 mid-life programme, Eurotunnel is signing a contract with Bombardier Transportation to renovate nine “PAX” Shuttles. Composed in total of 254 wagons, each 800-meter long shuttle is made up for passengers’ vehicles with passengers remaining in their vehicles during for the 35-minute Channel crossing. In the 25-year period since the opening of the Channel Tunnel, these Shuttles have each travelled an average of 300 round trips per month and have enabled over 236 million passengers to travel very comfortably between France and Great-Britain. The contract is valued at €150 million ($171 million) over a period of 7 years. Deliveries of the newly refurbished Shuttles will start in mid-2022 and continue until mid-2026. Teams from Bombardier France and Belgium1 originally designed and built these unique vehicles in the 90’s and launched Bombardier’s activities in France. This year, the company celebrates 30 years since its est